Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | MPL | P40238 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868718 | 0.85 | SRC (0.54) | SRCPTGS2MAPTALOX15SMN1; SMN2 | |
| SCHEMBL29467934 | 0.85 | SRC (0.54) | SRCPTGS2MAPTALOX15SMN1; SMN2 | |
| SCHEMBL10862456 | 0.85 | P2RX7 (0.45) | SRCPTGS2MAPTALOX15SMN1; SMN2 | |
| SCHEMBL3228305 | 0.84 | SRC (0.62) | SRCPTGS2MAPTALOX15SMN1; SMN2 | |
| SCHEMBL29481933 | 0.84 | SRC (0.62) | SRCPTGS2MAPTALOX15SMN1; SMN2 | |
| SCHEMBL31481088 | 0.83 | P2RX7 (0.47) | SRCFFAR1FFAR4P2RX7ALDH1A1 | |
| SCHEMBL17653927 | 0.83 | P2RX7 (0.47) | SRCFFAR1FFAR4P2RX7ALDH1A1 | |
| SCHEMBL12258207 | 0.82 | SRC (0.65) | SRCPTGS2MAPTALOX15SMN1; SMN2 | |
| SCHEMBL16379386 | 0.81 | P2RX7 (0.43) | SRCPTGS2ABCB11PTGS1PPARG | |
| Ethylenediamine SCHEMBL14844383 | 0.81 | SRC (0.56) | SRCPTGS2MAPTALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109809383-A | A kind of synthetic method of anti-cabbage black rot bacterium selenium carbon material | 扬州大学 | 2019-05-28 | — | — | CN | claimed |
| US-12145927-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-11-19 | — | — | US | disclosed |
| CN-114984003-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2024-08-27 | — | — | CN | disclosed |
| US-12059420-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| CN-115054600-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2024-06-14 | — | — | CN | disclosed |
| US-11524938-B2 | Aromatic sulfonamide derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20220324807-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-10-13 | — | — | US | disclosed |
| CN-115054600-A | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114984003-A | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-109415321-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| WO-2009050183-A2 | IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| EP-1885695-B1 | INDOLINE COMPOUNDS | FOURNIER LAB SA (FR) | 2009-02-25 | — | — | EP | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| WO-2007000550-A2 | NOVEL INDOLINE COMPOUNDS | LABORATOIRES FOURNIER S.A. (FR) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210641-A1 | Organic Compounds | ALK, ACVR1, ACVRL1 | SRC 1471/4885PTGS2 2933/4885MAPT 2453/4885 |
| US-20220324807-A1 | AROMATIC SULFONAMIDE DERIVATIVES | ARSA, SULT2A1, TPST2 | SRC 867/4885PTGS2 2521/4885MAPT 1230/4885 |
| US-11524938-B2 | Aromatic sulfonamide derivatives | ARSA, SULT2A1, TPST2 | SRC 867/4885PTGS2 2521/4885MAPT 1230/4885 |
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | SRC 2376/4885PTGS2 2867/4885MAPT 763/4885 |
| US-12059420-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | SRC 1630/4885PTGS2 86/4885MAPT 3649/4885 |
| US-12145927-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | SRC 1593/4885PTGS2 98/4885MAPT 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.